Design, Synthesis, and Structure-Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/224460

Citation

Colis , L , Ernst , G , Sanders , S , Liu , H , Sirajuddin , P , Peltonen , K , DePasquale , M , Barrow , J C & Laiho , M 2014 , ' Design, Synthesis, and Structure-Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors ' , Journal of Medicinal Chemistry , vol. 57 , no. 11 , pp. 4950-4961 . https://doi.org/10.1021/jm5004842

Titel: Design, Synthesis, and Structure-Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors
Författare: Colis, Laureen; Ernst, Glen; Sanders, Sara; Liu, Hester; Sirajuddin, Paul; Peltonen, Karita; DePasquale, Michael; Barrow, James C.; Laiho, Marikki
Upphovmannens organisation: Faculty of Pharmacy
Cancer Molecular biology and Therapeutics
Datum: 2014-06-12
Språk: eng
Sidantal: 12
Tillhör serie: Journal of Medicinal Chemistry
ISSN: 0022-2623
DOI: https://doi.org/10.1021/jm5004842
Permanenta länken (URI): http://hdl.handle.net/10138/224460
Abstrakt: RNA polymerase I (Pol I) is a dedicated polymerase that transcribes the 45S ribosomal (r) RNA precursor. The 45S rRNA precursor is subsequently processed into the mature 5.8S, 18S, and 28S rRNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. On the basis of the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides have been evaluated as inhibitors of Pol I and activators of the destruction of RPA194, the Poll large catalytic subunit protein. Structure-activity relationships in assays of nucleolar stress and cell viability demonstrate key pharmacophores and their physicochemical properties required for potent activation of Pol I stress and cytotoxidty. This work identifies a set of bioactive compounds that potently cause RPA194 degradation that function in a tightly constrained chemical space. This work has yielded novel derivatives that contribute to the development of Pol I inhibitory cancer therapeutic strategies.
Subject: CANCER
TRANSCRIPTION
DISCOVERY
NUCLEOLUS
MECHANISM
STRATEGY
317 Pharmacy
Referentgranskad: Ja
Licens: other
Användningsbegränsning: openAccess
Parallelpublicerad version: publishedVersion


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
jm5004842.pdf 560.4Kb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post